Perceptive is a privately held clinical research organisation headquartered at 58 Grosvenor Street, London, United Kingdom, with its US headquarters in Burlington, Massachusetts and global laboratories based in Needham, Massachusetts. The company operates across three integrated business divisions — Perceptive Discovery, Perceptive eClinical, and Perceptive Imaging — each led by a dedicated Chief Executive Officer, enabling focused operational leadership within a unified group structure.

The company draws on over 50 years of combined experience across its constituent businesses and has supported more than 11,000 clinical trial implementations, over 800 regulatory approvals, and more than 3,000 preclinical studies. Its client base spans global pharmaceutical companies, emerging biotechs, and contract research organisations operating across North America, Europe, and Asia-Pacific.

Perceptive’s current structure reflects a consolidation of several specialist businesses, including the acquisition of Invicro, a preclinical and translational imaging company embedded within Barts Cancer Institute at Queen Mary University of London and Duke University in Durham, North Carolina, as well as the former Calyx eClinical business. These acquisitions have positioned Perceptive as a multi-capability provider able to support sponsors from early discovery through to post-market surveillance under a single operational umbrella.

The company maintains offices and facilities in the UK (London, Nottingham), United States (Burlington MA, Needham MA, Durham NC, Mattawan MI), Germany (Berlin), India (Hyderabad), China (Shanghai), and Japan (Tokyo), providing direct on-the-ground support for global clinical programmes.

Key Products and Services

Perceptive Discovery

• Preclinical Imaging — in vivo small animal imaging using PET, SPECT, MRI, CT, optical, and ultrasound modalities; quantitative image analysis via the proprietary VivoQuant™ software platform; translational imaging bridging preclinical findings to clinical endpoints
• In-House Clinical and Imaging Centres — dedicated imaging facilities at Imperial College London (Hammersmith Hospital) and Barts Cancer Institute, providing first-in-human and early-phase clinical imaging capabilities on-site
• Radiochemistry — synthesis and supply of radiolabelled tracers for PET and SPECT imaging studies, including GMP radiopharmaceutical production
• Biodistribution Services — quantitative measurement of radiotracer or drug distribution across tissues in preclinical models
• Radioligand Binding Assay Services — in vitro receptor binding assays supporting target engagement and pharmacology studies for radioligand therapy programmes

Perceptive eClinical

• IRT/RTSM (Interactive Response Technology / Randomisation and Trial Supply Management) — cloud-based platform managing patient randomisation, drug supply forecasting, depot management, kit assignment, and unblinding workflows across global clinical trials; supports adaptive and complex study designs
• eCOA (Electronic Clinical Outcome Assessment) — patient- and clinician-reported outcome capture via electronic diary and tablet-based platforms, with validated instruments across therapeutic areas
• Clinical Intelligence — data analytics and reporting tools providing sponsors and CROs with real-time trial performance insights, site metrics, and supply chain visibility

Perceptive Imaging (Imaging Core Lab)

• Centralised imaging core laboratory services for clinical trials, including image collection, de-identification, quality control, and central radiological review
• Dual-read and adjudication workflows across established response criteria including RECIST 1.1, iRECIST, RANO/RANO 2.0, Lugano criteria, and others
• Quantitative imaging endpoint generation across CT, MRI, PET, and X-ray modalities
• Regulatory-submission-ready imaging packages and medical writing support

Therapeutic Area Coverage

Clinical: Oncology (solid tumours and haematology), CNS and neuroscience, radiopharmaceutical therapy and theranostics, rare diseases, musculoskeletal, obesity and weight management, cardiovascular, and immunology

Preclinical: Oncology, radioligand therapy, CNS and translational neuroscience, and metabolic disease

Perceptive occupies a distinctive position in the clinical research services landscape by combining three capabilities — preclinical and translational imaging, clinical trial imaging, and RTSM — that are typically sourced from separate specialist vendors. This integration is strategically relevant for sponsors developing complex modalities such as radioligand therapies and theranostics, where a continuous imaging thread from preclinical biodistribution through to clinical dosimetry and response assessment is operationally and scientifically advantageous. The company’s embedded clinical imaging centres at Imperial College London and Barts Cancer Institute provide an unusual first-in-human imaging capability that few CROs can offer within their own infrastructure. With over 11,000 trials implemented and 800+ regulatory approvals supported, Perceptive’s operational track record is substantial, and its multi-divisional structure — each led by domain-specialist leadership with backgrounds at IQVIA, Parexel, PPD, Precision Medicine Group, and Curium Pharma — reflects an organisation consolidating depth of expertise rather than breadth of generalist CRO services.